Absci Accelerates Drug Trials for Hair Loss–is Its AI Pipeline Turning a Corner?
Posted3 months agoActive3 months ago
simplywall.stResearchstory
calmpositive
Debate
0/100
AI in HealthcareBiotechDrug Development
Key topics
AI in Healthcare
Biotech
Drug Development
Absci is accelerating drug trials for hair loss using its AI pipeline, sparking interest in the potential of its technology; the limited discussion suggests a wait-and-see approach from the community.
Snapshot generated from the HN discussion
Discussion Activity
Light discussionFirst comment
7m
Peak period
1
0-1h
Avg / period
1
Key moments
- 01Story posted
Oct 16, 2025 at 6:29 PM EDT
3 months ago
Step 01 - 02First comment
Oct 16, 2025 at 6:36 PM EDT
7m after posting
Step 02 - 03Peak activity
1 comments in 0-1h
Hottest window of the conversation
Step 03 - 04Latest activity
Oct 16, 2025 at 6:36 PM EDT
3 months ago
Step 04
Generating AI Summary...
Analyzing up to 500 comments to identify key contributors and discussion patterns
Discussion (1 comments)
Showing 1 comments
randycupertinoAuthor
3 months ago
Absci's (ABSI) crown jewel, ABS-201, is supposed to regrow hair better than minoxidil, and they’re partnering with AMD and Oracle for AI-based drug development and AI-designed antibodies. If they actually work in humans it will be huge. Their valuation hangs entirely on whether their first clinical programs (ABS-101 and ABS-201) validate the tech, otherwise yet another AI drug hype that never cleared clinical trials. Watching this one!
View full discussion on Hacker News
ID: 45611464Type: storyLast synced: 11/17/2025, 10:09:55 AM
Want the full context?
Jump to the original sources
Read the primary article or dive into the live Hacker News thread when you're ready.